相关实验视频

Updated: Jul 13, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

梅特福明和 thiazolidinedione 在医疗保险心力衰竭患者的使用

Frederick A Masoudi¹, Yongfei Wang, Silvio E Inzucchi

¹Division of Cardiology, Department of Medicine, Denver Health Medical Center, Colorado, USA.

|July 3, 2003

概括

糖尿病患者心力衰竭中使用甲胺和 thiazolidinediones 的数量显著增加,尽管有FDA 的警告. 需要进一步的研究,以确保患者的安全和最佳的治疗策略.

科学领域:

心脏病学心脏病学
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

甲胺在心力衰竭患者中是禁忌的,而在晚期心力衰竭患者中不建议使用 thiazolidinediones.
关于这些抗高血糖药物在心力衰竭糖尿病患者的使用模式的数据有限.

研究的目的:

确定在患有糖尿病和心力衰竭的住院患者中甲福明和 thiazolidinediones 的处方趋势.

主要方法:

利用了从回顾性医疗记录抽象中得到的连续横截面测量.
分析了1998-1999年和2000-2001年期间因心力衰竭和糖尿病住院的两个国家医疗保险受益者样本的数据.

主要成果:

出院时的甲福明或 thiazolidinedione 的处方从 1998-1999 年的 13.5% 增加到 2000-2001 年的 24.4%.
在研究期间,甲胺的使用量从7.1%增加到11.2%, thiazolidinedione的使用量从7.2%增加到16.1%.
这一趋势在所有人口群体中都是一致的.

结论:

与FDA警告相反,在心力衰竭的糖尿病患者中,甲胺和 thiazolidinedione 的使用普遍且快速增加.
进一步的研究是必要的,以评估这些药物的安全性和有效性在这个患者群体.
为了确保糖尿病和心力衰竭患者的最佳护理,需要进一步调查这些处方模式.

更多相关视频

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

相关概念视频

Antihypertensive Drugs: Thiazide-Class Diuretics

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...